Abstract
The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.
Introduction: Addressing the "One Size Does Not Fit All" Challenge
Clinical guidelines for gynecologic oncology, such as those from the National Comprehensive Cancer Network (NCCN), are largely based on data from Western populations. However, differences in genetics, environment, and healthcare infrastructure mean that Asian patients may require distinct surgical approaches or therapeutic dosages. The 2018 Asian Society of Gynecologic Oncology (ASGO) International Workshop aimed to bridge this gap by synthesizing regional data and standardizing high-tech interventions within the Asian context.
A primary focus was the "MIS Crisis" in cervical cancer, where recent trials suggested that minimally invasive surgery (MIS) might result in worse survival rates than traditional open surgery. The workshop provided a platform to discuss whether these findings apply universally or if specific technical modifications could preserve the benefits of MIS for Asian patients.
Methodology and Regional Data Synthesis
The workshop functioned as a multi-disciplinary synthesis of expert presentations, clinical trial updates, and consensus-building sessions. Key areas of focus included:
- Clinical Review: Analysis of major trials (e.g., LACC, GOG 213, ICON7) and their implications for Asian practice.
- Surgical Innovation: Evaluation of 3D vs. 2D laparoscopy and radical trachelectomy for fertility preservation.
- Molecular Oncology: Discussion on PARP inhibitors, BRCA mutations, and Microsatellite Instability (MSI) in tailoring immunotherapy.
- Policy & Guidelines: Comparison of national guidelines from Japan, Korea, China, and Thailand to identify regional deviations from Western standards.
The discussions drew upon regional registries, such as the Niigata study (Japan) on HPV vaccine effectiveness and the Siriraj Hospital registry (Thailand) on venous thromboembolism, alongside re-analyses of global clinical trials through the lens of Asian patient cohorts.
Key Insights and Innovations
The Asian Advantage and Toxicity Profiles
Asian patients often exhibit better performance status and earlier-stage disease at trial enrollment compared to Western counterparts. However, they also show different toxicity profiles for certain chemotherapies, necessitating localized dosing studies to optimize treatment efficacy and safety.
The MIS Controversy and 3D Laparoscopy
The workshop highlighted that while the LACC trial showed higher recurrence rates in cervical cancer for MIS, the mechanical causes—such as CO2 pneumoperitoneum and tumor spillage during vaginal colpotomy—might be the true culprits. Furthermore, 3D laparoscopy emerged as a "skill equalizer," significantly reducing the learning curve for novice surgeons by restoring depth perception and improving performance scores by nearly 10% in complex tasks.
Drug Repositioning and Molecular Screening
A notable insight was the potential of statins to induce programmed cell death in ovarian cancer by interfering with the "Warburg effect." Additionally, in endometrial cancer, the high concordance (94.1%) between MSI testing and Immunohistochemical (IHC) staining validates IHC as a reliable, cost-effective screening tool for immunotherapy eligibility.
Significant Outcomes
- HPV Vaccination: In Japan, the bivalent vaccine is estimated to prevent approximately 82% of invasive cervical cancers.
- Ovarian Cancer Survival: The addition of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to interval debulking surgery improved median recurrence-free survival by 3.5 months in specific stage III cohorts.
- Surgical Precision: 3D systems led to faster operating times and fewer errors in complex suturing compared to 2D systems.
Challenges and Future Directions
Despite these advancements, several hurdles remain. Disparities in healthcare spending and access to high-tech imaging (like PET/MRI) persist across Asian nations. Legal and cultural barriers continue to slow the development of multi-center, international investigator-driven trials within the region. Future work must focus on resolving surgical questions regarding MIS in cervical cancer and increasing clinical trials for rare uterine tumors and mucinous ovarian subtypes.
Summary updated